Victoza: Advanced GLP-1 Therapy for Type 2 Diabetes Control
| Product dosage: 6mg | |||
|---|---|---|---|
| Package (num) | Per injector | Price | Buy |
| 1 | $387.00 | $387.00 (0%) | 🛒 Add to cart |
| 2 | $365.50
Best per injector | $774.00 $731.00 (6%) | 🛒 Add to cart |
Synonyms | |||
Victoza (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. This injectable medication mimics the action of endogenous GLP-1, enhancing glucose-dependent insulin secretion, suppressing glucagon secretion, and delaying gastric emptying. Clinical evidence supports its efficacy in lowering HbA1c, promoting weight loss, and offering cardiovascular benefits for appropriate patient populations.
Features
- Active ingredient: Liraglutide (6 mg/mL)
- Delivery: Prefilled, multi-dose pen (3 mL)
- Administration: Subcutaneous injection
- Dosing: Once daily, any time of day
- Available strengths: 6 mg/mL delivering doses of 0.6 mg, 1.2 mg, or 1.8 mg
- Prescription-only medication
Benefits
- Significantly reduces HbA1c levels through glucose-dependent mechanisms
- Promotes moderate weight loss in many patients
- Demonstrates cardiovascular risk reduction in patients with established CVD
- Lowers risk of hypoglycemia compared to insulin and sulfonylureas
- Offers flexible once-daily dosing without strict timing requirements
- May improve beta-cell function and slow disease progression
Common use
Victoza is primarily prescribed for adults with type 2 diabetes mellitus whose blood sugar is not adequately controlled with diet and exercise alone or with other antidiabetic medications. It is commonly used in combination with metformin, sulfonylureas, or basal insulin when additional glycemic control is needed. The medication is particularly valuable for patients who would benefit from weight loss and those with established cardiovascular disease requiring agents with proven cardiovascular benefit.
Dosage and direction
Initiate Victoza at 0.6 mg subcutaneously once daily for at least one week to reduce gastrointestinal symptoms. Increase to 1.2 mg daily. If additional glycemic control is needed after at least one week, the dose may be increased to 1.8 mg daily. Administer at any time of day, independently of meals. Inject subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy. Prime the pen before first use. Do not mix with insulin or other medications.
Precautions
Monitor renal function periodically, as cases of acute kidney injury and worsening chronic renal failure have been reported, typically in association with nausea, vomiting, diarrhea, or dehydration. Use with caution in patients with a history of pancreatitis. Observe patients for signs and symptoms of pancreatitis (including persistent severe abdominal pain). Thyroid C-cell tumors have been observed in rodent studies; relevance to humans unknown. Not recommended as first-line therapy for patients inadequately controlled on diet and exercise. Not for treatment of type 1 diabetes or diabetic ketoacidosis.
Contraindications
Victoza is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Hypersensitivity to liraglutide or any product components. Do not use in patients with severe gastrointestinal disease, including gastroparesis.
Possible side effects
Most common adverse reactions (≥5%) include nausea, diarrhea, vomiting, decreased appetite, dyspepsia, and constipation. Hypoglycemia is more common when used with sulfonylureas or insulin. Other reported effects: injection site reactions, tachycardia, fatigue, dizziness, abdominal pain, headache. Serious but rare side effects may include pancreatitis, allergic reactions, renal impairment, and gallbladder disease.
Drug interaction
Victoza delays gastric emptying and may impact absorption of orally administered medications. Monitor drugs with narrow therapeutic index (e.g., warfarin) when initiating or adjusting Victoza dosage. Concomitant use with insulin or insulin secretagogues may increase hypoglycemia risk; consider dose reduction of these agents. No clinically significant interaction observed with common substrates of CYP450 enzymes.
Missed dose
If a dose is missed, it should be administered as soon as possible on the same day. Do not administer two doses on the same day. Resume the regular dosing schedule the following day. Do not administer extra doses or increase the next dose to make up for a missed dose.
Overdose
Effects of overdose may include severe nausea, vomiting, and hypoglycemia. In case of overdose, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms. Because liraglutide has a prolonged duration of action, monitor and treat supportively for an extended period. Hemodialysis is unlikely to be effective due to high protein binding.
Storage
Store unused Victoza pens refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. After first use, store at room temperature (below 30°C/86°F) or refrigerated. Discard after 30 days, even if some medication remains. Keep out of reach of children. Do not use if frozen or if exposed to temperatures above 30°C.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Victoza should be used only under the supervision of a qualified healthcare provider. Individual results may vary. Patients should discuss their medical condition, treatment options, and potential risks and benefits with their physician. Always follow the prescribed dosage and administration instructions.
Reviews
Clinical trials demonstrate Victoza’s efficacy in glycemic control with mean HbA1c reductions of 1.0% to 1.5% from baseline. The LEADER trial showed a 13% reduction in major adverse cardiovascular events. Real-world evidence supports sustained HbA1c reduction and weight loss (average 2-3 kg) over 6-12 months. Most patients tolerate the medication well, though gastrointestinal side effects may diminish over time. Healthcare providers report particular success in motivated patients who benefit from both glycemic improvement and weight management.